Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06089824 · ClinicalTrials.gov registry record
Drug Utilisation of Mysimba/Contrave
A clinical trial, sponsored by Currax Pharmaceuticals.
- Completed
- Registry status
- 43,324
- Enrollment target
NCT06089824 is a clinical trial that has completed, run by Currax Pharmaceuticals. The registered enrollment target is 43,324 participants.
The verdict
NCT06089824 has completed, sponsored by Currax Pharmaceuticals.
- COMPLETED
- Registry status
- 43,324 participants
- Enrollment target
Study Summary
This study will assess a retrospective cohort of users of Mysimba/Contrave with up to 548 days (\~18 months) after initiation with treatment with Mysimba/Contrave. This study will describe Mysimba/Contrave utilisation and incidence of AESIs for users compliant and non-compliant with the SmPC.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43,324 participants |
| Start Date | 2014-09 |
| Est. Completion | 2022-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06089824
The ClinicalTrials.gov registry entry for NCT06089824 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 43,324 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Currax Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06089824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06089824 about?
NCT06089824 is a clinical study titled "Drug Utilisation of Mysimba/Contrave". This study will assess a retrospective cohort of users of Mysimba/Contrave with up to 548 days (\~18 months) after initiation with treatment with Mysimba/Contrave. This study will describe Mysimba/Contrave utilisation and incidence of AESIs for users compliant and non-compliant with the SmPC.
What is the current status of trial NCT06089824?
This trial is currently completed. The enrollment target is 43,324 participants. The study started on 2014-09. Estimated completion is 2022-10.
Who is sponsoring clinical trial NCT06089824?
This trial is sponsored by Currax Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.